As more patients started to use this medication, they discovered that they were losing weight due to the effect it had on their appetite, so Novo Nordisk did some more testing and decided to get it licensed for weight loss too
Projected revenue for each product from 2025 through 2030, based on consensus estimates from Wall Street analysts, are used to calculate the forecasted cumulative revenue to the end of the decade
POTS, like all inflammatory and autoimmune conditions, exists on a spectrum, and can be triggered by a combination of different factors
CHARMM-GUI Membrane Builder toward realistic biological membrane simulations
With these data, the safety profiles of rare potential events (e.g
This overview does not substitute for that documentation or for direct guidance from the prescribing clinician